口服抗癌治疗的依从性:临床试验与真实世界经验的对比,聚焦前列腺癌
本综述汇总真实世界前列腺癌口服药物依从性研究、依从障碍研究及改善依从性方法研究,发现前列腺癌口服治疗患者平均不依从率为25%至51%,老年患者更高;接受促性腺激素释放激素激动剂注射的前列腺癌患者总体不依从率超过27%。依从障碍涉及药物因素与患者因素,改善措施包括自动提醒、治疗日记、教育材料及患者、家属、照护伙伴和医疗团队的参与。
要点
- 前列腺癌口服治疗患者平均不依从率为25%至51%,老年患者不依从率更高。
- 接受促性腺激素释放激素激动剂注射的前列腺癌患者总体不依从率超过27%。
- 依从障碍涉及药物因素(如复杂给药方案、空腹或饮食要求、高药费、不良反应、药物相互作用)和患者因素(如教育不足、体力限制、认知衰退、独居无照护伙伴、高症状负担、针头恐惧、共病精神障碍)。
核心结论
- 许多口服抗癌药物可改善前列腺癌男性患者的生存,因此通过理解患者可能遇到的陷阱来建立良好的依从性至关重要。
- 在口服药物与注射药物可互换的情况下,长效药物注射比口服治疗导致更少的给药不依从机会。
- 相反,口服药物不需要安排注射和前往注射预约的行程。
- 因此,最大化所有治疗方案的依从性将减少疗效失败的机会,并可能改善临床结局。
研究设计与样本
- 本综述纳入报告前列腺癌药物真实世界依从性的4项研究、描述依从障碍的52项研究以及关于最小化不良依从性方法的16项研究。
主要发现
- 前列腺癌口服治疗患者平均不依从率为25%至51%,老年患者不依从率更高。
- 对接受促性腺激素释放激素激动剂注射的前列腺癌患者进行的广泛综述发现总体不依从率超过27%。
- 患者可能遇到与药物相关的依从障碍,例如复杂给药方案、药物管理的总负担、空腹或饮食要求、高药物费用、不良反应和药物相互作用。
- 依从障碍也可能与患者特定因素相关,例如关于依从重要性教育不足、与年龄增长相关的体力限制和认知衰退、独居无照护伙伴、高症状负担、针头恐惧和共病精神障碍。
- 改善给药依从性的干预措施可能包括自动提醒、治疗日记、教育材料以及患者、家庭成员、照护伙伴和医疗团队的参与。
临床怎么用
- 在口服药物与注射药物可互换的情况下,长效药物注射比口服治疗导致更少的给药不依从机会。
- 口服药物不需要安排注射和前往注射预约的行程。
- 最大化所有治疗方案的依从性将减少疗效失败的机会,并可能改善临床结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this review, we address adherence rates in clinical settings, barriers to compliance with dosing schedules, and potential strategies to overcome challenges in maintaining high levels of adherence. MATERIALS AND METHODS: Four studies reporting real-world adherence to prostate cancer medications, 52 studies describing barriers to adherence, and 16 studies on methods to minimize poor adherence were reviewed. RESULTS: Mean nonadherence rates of 25% to 51% have been identified in prostate cancer patients prescribed oral therapies, with higher rates in older patients. An extensive review of prostate cancer patients receiving gonadotropin hormone-releasing hormone agonist injections found an overall nonadherence rate of over 27%. Patients may encounter barriers to complying with dosing instructions related to the medication (eg, complex dosing schedules, the total burden of medication management, fasting or dietary requirements, high medication costs, adverse effects, and drug-drug interactions). Barriers may also be related to patient-specific factors (eg, suboptimal education regarding the importance of adherence, physical limitations and cognitive decline associated with advancing age, living alone without a care partner, high symptom burden, needle phobia, and comorbid mental disorders). Interventions to improve dosing adherence may include automated reminders, treatment diaries, educational materials, and the involvement of patients, family members, care partners, and health care teams. CONCLUSIONS: Many oral anticancer medications improve survival in men with prostate cancer, and therefore it is vital to establish good adherence by understanding the pitfalls that patients may encounter. In situations where both oral and injectable drugs are interchangeable, injections of long-acting drugs lead to fewer opportunities for dosing nonadherence than oral therapies. In contrast, oral medicines do not require scheduling for injections and travel for injection appointments. Therefore, maximizing adherence to all treatment regimens will reduce the chance of efficacy failures and likely lead to improved clinical outcomes.
引用
- Higano CS, Hafron J. Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer. J Urol. 2022. PMID: 36472138. doi:10.1097/JU.0000000000003081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。